Holen Sie sich die Stockscreener-App
13.26
1.41%
-0.19
Schlusskurs vom Vortag:
$13.45
Offen:
$13.66
24-Stunden-Volumen:
804.58K
Relative Volume:
0.18
Marktkapitalisierung:
$940.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-117.81M
KGV:
-7.0532
EPS:
-1.88
Netto-Cashflow:
$74.30M
1W Leistung:
-19.05%
1M Leistung:
+15.61%
6M Leistung:
+292.31%
1J Leistung:
+34.07%
1-Tages-Spanne:
$13.18
$14.25
1-Wochen-Bereich:
$13.18
$16.39
52-Wochen-Spanne:
$2.95
$17.65
Omeros Corporation Stock (OMER) Company Profile
Firmenname
Omeros Corporation
Sektor
Branche
Telefon
206-676-5000
Adresse
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Vergleichen Sie OMER mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
13.27 | 953.61M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.67 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.37 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
813.75 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.69 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-23 | Eingeleitet | D. Boral Capital | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-12-08 | Herabstufung | UBS | Buy → Neutral |
| 2022-11-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-06-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-10-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2021-10-01 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-09-27 | Eingeleitet | JP Morgan | Neutral |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-08-21 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-14 | Bestätigt | Maxim Group | Buy |
| 2019-05-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-12 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-23 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-03-05 | Herabstufung | Needham | Buy → Hold |
| 2017-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Herabstufung | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | Bestätigt | Maxim Group | Buy |
| 2017-03-17 | Bestätigt | Needham | Buy |
| 2016-11-16 | Bestätigt | Wedbush | Outperform |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-08-10 | Bestätigt | Maxim Group | Buy |
| 2016-06-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-02 | Bestätigt | Needham | Buy |
| 2016-02-29 | Bestätigt | Wedbush | Outperform |
| 2015-11-11 | Bestätigt | Needham | Buy |
| 2015-08-18 | Bestätigt | WBB Securities | Strong Buy |
| 2015-08-10 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Omeros Corporation Aktie (OMER) Neueste Nachrichten
What is HC Wainwright's Forecast for Omeros Q1 Earnings? - MarketBeat
Fundamentals Check: Will Omeros Corporation stock see insider buyingMarket Growth Report & Daily Stock Momentum Reports - ulpravda.ru
Why Omeros Corporation stock could benefit from AI revolutionJuly 2025 Technicals & Growth-Oriented Investment Plans - ulpravda.ru
Why retail investors pile into Omeros Corporation stock2025 Sector Review & Technical Entry and Exit Tips - ulpravda.ru
Omeros (NASDAQ:OMER) Trading Up 10.3% on Analyst Upgrade - MarketBeat
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set - TechStock²
OMER: HC Wainwright & Co. Raises Price Target to $40 with Buy Ra - GuruFocus
OMER's Rating Maintained as 'Buy' with $36 Price Target by Analyst | OMER Stock News - GuruFocus
Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros - TipRanks
Omeros (NASDAQ:OMER) Price Target Raised to $40.00 - MarketBeat
Omeros (NASDAQ:OMER) Earns Buy Rating from D. Boral Capital - MarketBeat
Omeros Stock Enters Commercial Phase with Key Drug Launch - AD HOC NEWS
Omeros prices transplant complication drug at $36,000 per dose - whbl.com
Why did Omeros stock jump 5% in after-hours trading today? - MSN
Why Did Omeros Stock Jump 5% In After-Hours Trading Today? - Stocktwits
Omeros Details Yarcomlia U.S. Launch After FDA Approval, Pricing and Supply Outlook in Focus - MarketBeat
Is Omeros Corporation stock attractive for income investorsGrowth Stock Opportunities & Affordable Investment Portfolio - ulpravda.ru
Can Omeros Corporation stock deliver surprise earnings beatDay Trading Setups & Outstanding Growth Portfolio - ulpravda.ru
Omeros Corporation (OMER): Novo Nordisk deal creating buzz - MSN
Omeros (NASDAQ:OMER) Trading Down 6%Should You Sell? - MarketBeat
Assessing Omeros (OMER) Valuation After YARTEMLEA’s FDA Approval And Planned US Launch - simplywall.st
Will FDA Approval of YARTEMLEA in TA-TMA Redefine Omeros' (OMER) Commercial Trajectory? - simplywall.st
Omeros (NASDAQ:OMER) Sets New 12-Month HighStill a Buy? - MarketBeat
Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Omeros stock jumps premarket after FDA approves first drug for rare transplant complication — retail sees big upside - MSN
Will Omeros Corporation stock deliver better than expected guidanceGrowth Stock Opportunities & Ride the Wave of Market-Beating Growth - bollywoodhelpline.com
Omeros (NASDAQ:OMER) Trading Up 4.6%Here's Why - MarketBeat
Best Pharmaceutical Stocks To Watch TodayDecember 24th - MarketBeat
Retail’s Christmas Eve watchlist: Omeros, Nike, Citi, Dynavax and Agios spark most market chatter - MSN
Commit To Buy Omeros At $10, Earn 26.6% Annualized Using Options - Nasdaq
Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA - Yahoo Finance
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - MSN
Omeros Corp Announces FDA Approval of YARTEMLEA for TA-TMA - TradingView — Track All Markets
Omeros (NASDAQ: OMER) secures FDA nod for YARTEMLEA in TA-TMA - Stock Titan
Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade) - Seeking Alpha
FDA Clears First Therapy for Transplant Associated Thrombotic Microangiopathy - prismedia.ai
Omeros to resume trading at 9:50 AM ET - MSN
D Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains buy rating - MSN
Why Omeros stock skyrocketed today - MSN
Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Caledonian Record
Omeros stock garners high retail attention ahead of FDA verdict for life-saving drug - MSN
Omeros scores its 1st FDA nod as stem cell transplant drug Yartemlea approved - Fierce Pharma
Omeros (NASDAQ:OMER) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Omeros rockets as FDA approves Yartemlea - The Pharma Letter
Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER) - The Globe and Mail
WBB Securities Reaffirms Their Buy Rating on Omeros (OMER) - The Globe and Mail
Omeros (OMER): Revisiting Valuation After a Powerful Multi‑Year Share Price Repricing - Yahoo Finance
Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook - TechStock²
Omeros wins FDA nod for transplant therapy - MSN
Omeros (NASDAQ:OMER) Hits New 12-Month HighTime to Buy? - MarketBeat
Finanzdaten der Omeros Corporation-Aktie (OMER)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):